Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16932316 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL23700760 | 1.00 | CTSC (1.00) | CTSCKCNH2 | |
| SCHEMBL31758535 | 0.89 | CTSC (0.90) | CTSCKCNH2 | |
| Brensocatib SCHEMBL16932317 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL29363739 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30025888 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL19826706 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30901221 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL19813196 | 0.87 | CTSC (1.00) | CTSCKCNH2 | |
| Brensocatib SCHEMBL30025597 | 0.87 | CTSC (1.00) | CTSCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479059-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA | Insmed Incorporated (US) | 2024-12-25 | — | — | EP | claimed |
| CN-118695864-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamide for the treatment of hidradenitis suppurativa | 英斯梅德股份有限公司 | 2024-09-24 | — | — | CN | claimed |
| EP-4423071-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | Insmed Incorporated (US) | 2024-09-04 | — | — | EP | claimed |
| CN-118159525-A | Specific N- (1-cyano-2-phenethyl) -1, 4-oxaazepane-2-carboxamides for the treatment of chronic sinusitis | 英斯梅德股份有限公司 | 2024-06-07 | — | — | CN | claimed |
| EP-4329767-A1 | CERTAIN-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS | Insmed Incorporated (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2023159120-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA | INSMED INCORPORATED (US) | 2023-08-24 | — | — | WO | claimed |
| CN-116157687-A | Methods for extracting neutrophil serine protease and treating dipeptidyl peptidase 1 mediated disorders | 英斯梅德股份有限公司 | 2023-05-23 | — | — | CN | claimed |
| WO-2023076615-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | INSMED INCORPORATED (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2022232573-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022232420-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | claimed |
| WO-2022140516-A1 | CERTAIN (25)-IV-[(LS')~ I-C YAN0-2-PHENYLETHYL·]- 1,4-OXAZEPANE-2- CARBOXAMIDES FOR TREATING BEHCET'S DISEASE | INSMED INCORPORATED (US) | 2022-06-30 | — | — | WO | claimed |
| US-20250144116-A1 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA | INSMED INCORPORATED (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250049813-A1 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | INSMED INCORPORATED | 2025-02-13 | — | — | US | disclosed |
| EP-3744714-B1 | (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2025-01-15 | — | — | EP | disclosed |
| EP-4479059-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA | Insmed Incorporated (US) | 2024-12-25 | — | — | EP | disclosed |
| US-11655224-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-05-23 | — | — | US | disclosed |
| WO-2022232573-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CYSTIC FIBROSIS | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022232420-A1 | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CANCER | INSMED INCORPORATED (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022140516-A1 | CERTAIN (25)-IV-[(LS')~ I-C YAN0-2-PHENYLETHYL·]- 1,4-OXAZEPANE-2- CARBOXAMIDES FOR TREATING BEHCET'S DISEASE | INSMED INCORPORATED (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022053019-A1 | METHODS FOR TREATING METASTASIS WITH CATHEPSIN C INHIBITORS | Shanghai Institute of nutrition and health, Chinese Academy of Sciences (CN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144116-A1 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING HIDRADENITIS SUPPURATIVA | DPP7, DPEP1, DPP8 | CTSC 15/4885KCNH2 2148/4885 |
| US-11655224-B2 | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | CTSC 7/4885KCNH2 2478/4885 |
| US-20250049813-A1 | CERTAIN N-(1-CYAN0-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING CHRONIC RHINOSINUSITIS | TPP1, DPP7, DPEP1 | CTSC 10/4885KCNH2 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.